23 results about "Brown Adipocyte" patented technology

Disclosed herein is a genetically engineered mesenchymal stem cells (MSC) comprising genetic alterations that increase gene expressions for adipogenic differentiation, mitochondrial biogenesis and a brown adipocyte marker. Also disclosed herein is a pharmaceutical composition and use of the pharmaceutical composition for preventing, ameliorating and / or treating a metabolic disorder.

To provide non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of making and using the same.SOLUTION: The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates. Also provided herein is an encapsulation system comprising non-naturally occurring 3D brown adipose-derived stem cell aggregates. The 3D brown adipose-derived stem cell aggregate may comprise brown adipose-derived stem cells that express one or more brown adipocyte gene in the absence of differentiation medium.SELECTED DRAWING: None

The invention relates to a compound for improving heat production and metabolic disorder of middle-aged and elderly people or obese individuals and application of the compound, in particular to application of betaine or an accelerant of the betaine, and particularly discloses application of the betaine or the accelerant of the betaine and application of the betaine or the accelerant of the betaine to preparation of a preparation or a pharmaceutical composition, and the preparation or the pharmaceutical composition is used for (a) adjusting heat production; and / or (b) ameliorating metabolic disorders. The betaine or the accelerant thereof can promote up-regulation of expression of heat-producing genes and / or expression of UCP1 in brown adipocytes, so that the body temperature is increased.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

Provided herein is a method for generating Gata6 positive brown adipose precursor cells and brown adipocytes and tissues therefrom.Furthermore, provided herein is a method for generating UCP1 positive organoids.Generally, this method comprises culturing brown adipose precursor cells in a medium that contains FGF signaling pathway activator, BMP signaling pathway activator, TGFβ activator, Wnt inhibitor and thyroid hormone receptor activator.

The invention discloses application of vitexin in preparation of medicines for preventing and treating obesity. According to the application of the vitexin in preparation of the medicine for preventing and treating the obesity, the prevention and treatment comprise one or more of prevention, relieving or treatment of the obesity induced by high fat diet, and the medicine can be generally a solution and contains pharmaceutically acceptable auxiliary materials. The vitexin disclosed by the invention can promote the heat production of brown adipocytes and increase the oxygen consumption; the expression of heat production marker protein UCP1 of brown fat and subcutaneous white fat tissues is increased, the metabolic rate of an organism is increased, obesity induced by high fat diet is resisted, and then insulin resistance is improved.

The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like. The brown adipocyte supernatant of the present invention is expected to be applied to the development of therapeutic agents and cosmetic products for glucose metabolism diseases.

An object of the present invention is to provide an anti-obesity composition and an oral composition that can promote the gene expression of proteins such as PGC1α and UCP1 related to brown adipocytes or their energy-consuming effects, and have the effect of promoting energy-consuming effects in brown adipocytes. The composition of the present invention contains irigenin and pinitol. The irigenin is preferably irigenin. The composition of the present invention is preferably used as an anti-obesity composition and an oral composition.

The invention relates to a downstream motion factor identification method and system for regulating brown fat metabolism and a storage medium, and relates to the technical field of bioinformatics, and the method comprises the following steps: (1) processing a sample and obtaining transcriptome original data; (2) difference analysis; (3) time sequence analysis; (4) enrichment analysis; (5) carrying out weighted gene co-expression network analysis; (6) machine learning; according to the method, downstream metabolism-promotion factors of brown adipocytes are identified by using RNA next-generation sequencing results, overall characteristics of transcriptomes are obtained through difference analysis, enrichment analysis and time sequence analysis, data are further reduced by using weighted gene co-expression network analysis and machine learning, and key regulatory genes are screened out; according to the invention, key regulation molecules capable of promoting metabolism of brown adipocytes can be found, and a new biological target is provided for treating obesity.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

The present application provides a novel medium composition for use in inducing differentiation of somatic cells into brown adipocytes. As the present application, for example, there can be mentioned a medium composition for use in inducing differentiation of somatic cells into brown adipocytes, which is characterized by comprising seven components of a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic. According to the present application, differentiation induction of somatic cells into brown adipocytes can be effectively performed. In addition, according to the present application, brown adipocytes can be effectively maintained.

The present invention proposes a new fixation method for transmission electron microscopy samples of brown adipose tissue to obtain better ultrastructures of mitochondria and lipid droplets. The fixation method of brown adipose tissue of rodents is optimized, mainly including increasing the concentration of paraformaldehyde in the pre-fixative from 2% to 4%; replacing the buffer of the post-fixative osmium tetroxide with an imidazole buffer; and adopting a fixation method combining cardiac perfusion and immersion. The structures of mitochondrial cristae and other membranous organelles of brown fat cells prepared by the new fixation method are more complete; lipid droplets appear as round structures with high electron density. The method was used to observe the increase in the density of mitochondrial cristae and the increase in lipid droplets in brown fat cells after cold adaptation. The new fixation method can better preserve the ultrastructure of organelles in brown fat cells, especially mitochondria and lipid droplets, and can be used to study the ultrastructural changes of this type of cells under different physiological or pathological conditions.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

The subject of the present invention is to provide a new manufacturing method that can directly transform or induce somatic cells to brown adipocytes using low molecular weight compounds without gene introduction. As the present invention, for example, a method for preparing brown adipocytes can be cited, which is a method for preparing brown adipocytes from somatic cells by direct differentiation induction, the method comprising: a step of culturing somatic cells in a serum-free differentiation induction medium in the presence of a selective PPARγ agonist and a cAMP inducer. According to the present invention, direct transformation or induction from somatic cells to brown adipocytes can be effectively performed without gene introduction. The brown adipocytes obtained using the present invention are useful as regenerative medicine, human brown adipocytes and human beige cell models, etc.

The invention provides a brown adipocyte in-vitro culture device, and relates to the field of adipocyte in-vitro culture, the brown adipocyte in-vitro culture device comprises a frame body, and an amplification assembly used for cell amplification and a separation assembly used for cell acquisition are spaced up and down in the frame body; the amplification assembly comprises a mounting plate arranged in an inner cavity of the frame body, rotating plates are arranged on the outer side of the mounting plate in a rectangular array mode, test tubes sleeve the middles of the rotating plates, a culture dish for cell culture sleeves the middle of the mounting plate, a cover plate is arranged at the top of the culture dish, and the cover plate is connected with the rotating plates. And the top of the cover plate is in pipe connection with a second sleeve. The frame body is sterilized through the arranged sterilization pipe and the sterilization nozzle installed at one end of the sterilization pipe, precursor cells are extracted through the separation assembly, cell amplification and induction are conducted in cooperation with the amplification assembly, automatic induction cultivation is achieved, sterilization operation is conducted, and bacterial infection is avoided.

Disclosed herein is a genetically engineered mesenchymal stem cells (MSC) comprising genetic alterations that increase gene expressions for adipogenic differentiation, mitochondrial biogenesis and a brown adipocyte marker. Also disclosed herein is a pharmaceutical composition and use of the pharmaceutical composition for preventing, ameliorating and / or treating a metabolic disorder.

The invention discloses a composition for promoting browning of white fat cells and a preparation method thereof, and belongs to the technical field of biological medicine, the composition is prepared from the following raw materials by weight: 5-8 parts of 2-BrO, 2-5 parts of anacaric acid, 1-2 parts of 8-cyclopentyl-1, 3-dipropyl xanthine (DPCPX), 1-2 parts of endothelin-31, 0.1-0.5 part of S-4-nitrobenzyl-6-thioinosine (NBTI), and 1-2 parts of catecholamine. The liposome of which the surface is modified by the CKGGRAKDC is used as a carrier for targeting white fat cells, and the carrier for targeting the white fat cells is coated with 2-BrO, anacardic acid, S-4-nitrobenzyl-6-thioinosine, endothelin-3 and catecholamine. The finally prepared composition for promoting browning of white adipocytes promotes fat in adipose tissues to be decomposed into fatty acid, enhances the beta oxidation effect of the fatty acid, improves heat production efficiency, maintains normal reactivity of fat decomposition, and effectively promotes the white adipocytes to be browned into brown adipocytes.

It is an object of the present invention to provide an anti-obesity composition and an oral administration composition that can promote the gene expression of proteins such as PGC1α and UCP1 that are involved in brown adipocytes and the energy consumption activity of the brown adipocytes, and have the effect of promoting the energy consumption activity in the brown adipocytes. The compositions of the present invention contain a tectorigenin-like substance and pinitol. The tectorigenin-like substance is preferably tectorigenin. The compositions of the present invention can suitably be used as an anti-obesity composition or an oral administration composition.

The present invention relates to a novel triazole derivative or a salt thereof. The triazole derivative or the salt thereof according to the present invention induces or promotes browning of white adipocytes, and differentiates stem cells, embryonic cells, or preadipocytes to brown adipocytes or beige adipocytes. A composition comprising the triazole derivative or the salt thereof according to the present invention can treat, prevent, or alleviate obesity, obesity complications, diabetes, dyslipidemia, fatty liver, hypertension, metabolic syndrome, and insulin resistance syndrome.

The invention provides application of Asprosin (ASP) as a molecular marker in regulation and control of brown adipocyte ferroptosis, and relates to the technical field of biological medicine. A CRISPR-Cas9 technology is adopted to establish an ASP defect model with brown adipocytes as objects, it is found that ASP defect intervention can affect the level of ferroptosis related indexes, and meanwhile it is found that Notch3 as a downstream target of ASP plays an important role in the ferroptosis process of the brown adipocytes. The ASP and Notch3 are prompted to provide a new thought for developing a treatment strategy for brown adipocyte ferroptosis.

Provided herein are methods of generating Gata6-positive brown adipose progenitor cells, and brown adipose cells and tissue therefrom. Additionally, provided herein are methods of generating UCP1 positive organoids. Generally, the methods include a step of culturing brown adipose progenitor cells in a medium containing an FGF signaling pathway activator, a BMP signaling pathway activator, a TGFβ activator, a Wnt inhibitor, and a thyroid hormone receptor activator.